We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...

The first ticket draw entry period for the FIFA World Cup 26™ is now open at FIFA.com/tickets. As Canada, Mexico and the United States prepare to welcome the world ...

Abstract: To reduce the bit-error-rate (BER), equalizers are implemented in high-speed SerDes receivers (RX) to compensate for channel insertion loss and mitigate intersymbol interference (ISI).

ILWACO — The development of a new campus in Ilwaco has reached the next step in a yearslong process while the Ocean Beach School District continues its pursuit for tens of millions of dollars in state ...

Abstract: The single-stage isolated power factor correction (PFC) AC-DC DAB converters have gained increasing attention for battery-charging applications, including electric vehicle (EV) chargers and ...

The biggest stories of the day delivered to your inbox.

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Genshin Impact's "Luna 5" (or better known as 6.4) patch is coming soon, bringing us back to Mondstadt and giving us Varka as a playable character, finally. Genshin Impact will go down for maintenance ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

They can only be unlocked through a special redemption code included with any $50 purchase from 5.11 online or at U.S. retail stores. Battlefield players will need to make a purchase of a minimum of ...

- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, ...

Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s obesity blockbuster Zepbound in a phase 3 weight loss study, further denting the Danish pharma’s attempts to reclaim its obesity crown.